Drug Profile
Umbilical cord mesenchymal stem cell therapy - Alliancells Bioscience
Alternative Names: UC-MSC - Alliancells BioscienceLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Alliancells Bioscience
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cirrhosis; Rheumatoid arthritis
Most Recent Events
- 16 Feb 2016 No development reported - Phase-I/II for Cirrhosis in China (IV)
- 14 Apr 2015 No development reported - Phase-I/II for Rheumatoid arthritis in China (IV)
- 01 Jul 2014 Phase-I/II clinical trials in Cirrhosis in China (IV)